nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—sarcoma	0.461	1	CbGaD
Afatinib—ABCG2—Dactinomycin—sarcoma	0.0513	0.212	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—sarcoma	0.0459	0.19	CbGbCtD
Afatinib—ABCG2—Vincristine—sarcoma	0.0316	0.131	CbGbCtD
Afatinib—ABCG2—Etoposide—sarcoma	0.0289	0.12	CbGbCtD
Afatinib—ABCG2—Doxorubicin—sarcoma	0.0197	0.0818	CbGbCtD
Afatinib—ABCB1—Dactinomycin—sarcoma	0.0185	0.0766	CbGbCtD
Afatinib—ABCB1—Mitoxantrone—sarcoma	0.0165	0.0685	CbGbCtD
Afatinib—ABCB1—Vincristine—sarcoma	0.0114	0.0472	CbGbCtD
Afatinib—ABCB1—Etoposide—sarcoma	0.0104	0.0432	CbGbCtD
Afatinib—ABCB1—Doxorubicin—sarcoma	0.00712	0.0295	CbGbCtD
Afatinib—ERBB2—mammary gland—sarcoma	0.00219	0.0386	CbGeAlD
Afatinib—ERBB4—mammary gland—sarcoma	0.00219	0.0386	CbGeAlD
Afatinib—DYRK1A—mammary gland—sarcoma	0.0021	0.0371	CbGeAlD
Afatinib—BLK—hematopoietic system—sarcoma	0.00194	0.0343	CbGeAlD
Afatinib—EGFR—mammary gland—sarcoma	0.00185	0.0327	CbGeAlD
Afatinib—Vandetanib—TEK—sarcoma	0.00172	0.267	CrCbGaD
Afatinib—ERBB2—embryo—sarcoma	0.00149	0.0263	CbGeAlD
Afatinib—ERBB4—embryo—sarcoma	0.00149	0.0263	CbGeAlD
Afatinib—BLK—lymphoid tissue—sarcoma	0.00137	0.0241	CbGeAlD
Afatinib—ERBB2—hematopoietic system—sarcoma	0.00133	0.0235	CbGeAlD
Afatinib—ERBB2—connective tissue—sarcoma	0.00128	0.0226	CbGeAlD
Afatinib—DYRK1A—hematopoietic system—sarcoma	0.00128	0.0226	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—sarcoma	0.00117	0.0207	CbGeAlD
Afatinib—ERBB2—skin of body—sarcoma	0.00116	0.0204	CbGeAlD
Afatinib—Vandetanib—PDGFRB—sarcoma	0.00111	0.172	CrCbGaD
Afatinib—HIPK4—testis—sarcoma	0.00106	0.0188	CbGeAlD
Afatinib—ERBB4—cardiac atrium—sarcoma	0.00101	0.0178	CbGeAlD
Afatinib—ERBB2—uterus—sarcoma	0.00101	0.0177	CbGeAlD
Afatinib—IRAK1—hematopoietic system—sarcoma	0.000996	0.0176	CbGeAlD
Afatinib—PHKG2—tendon—sarcoma	0.00098	0.0173	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—sarcoma	0.000938	0.0165	CbGeAlD
Afatinib—ABL1—mammary gland—sarcoma	0.000916	0.0162	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—sarcoma	0.000903	0.0159	CbGeAlD
Afatinib—Vandetanib—SRC—sarcoma	0.000894	0.139	CrCbGaD
Afatinib—ERBB4—tendon—sarcoma	0.000881	0.0156	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—sarcoma	0.000877	0.0155	CbGeAlD
Afatinib—EGFR—uterus—sarcoma	0.000853	0.015	CbGeAlD
Afatinib—EPHA6—testis—sarcoma	0.000842	0.0149	CbGeAlD
Afatinib—Vandetanib—KDR—sarcoma	0.00084	0.13	CrCbGaD
Afatinib—PHKG2—testis—sarcoma	0.000812	0.0143	CbGeAlD
Afatinib—BLK—lymph node—sarcoma	0.000772	0.0136	CbGeAlD
Afatinib—PHKG2—liver—sarcoma	0.000767	0.0135	CbGeAlD
Afatinib—LCK—uterus—sarcoma	0.000734	0.0129	CbGeAlD
Afatinib—ERBB2—testis—sarcoma	0.00073	0.0129	CbGeAlD
Afatinib—ERBB4—testis—sarcoma	0.00073	0.0129	CbGeAlD
Afatinib—Vandetanib—VEGFA—sarcoma	0.000712	0.11	CrCbGaD
Afatinib—DYRK1A—testis—sarcoma	0.000703	0.0124	CbGeAlD
Afatinib—ERBB2—liver—sarcoma	0.00069	0.0122	CbGeAlD
Afatinib—DYRK1A—liver—sarcoma	0.000664	0.0117	CbGeAlD
Afatinib—IRAK1—tendon—sarcoma	0.000659	0.0116	CbGeAlD
Afatinib—ABL1—myometrium—sarcoma	0.00065	0.0115	CbGeAlD
Afatinib—IRAK1—bone marrow—sarcoma	0.000639	0.0113	CbGeAlD
Afatinib—ABL1—embryo—sarcoma	0.000625	0.011	CbGeAlD
Afatinib—LCK—bone marrow—sarcoma	0.000623	0.011	CbGeAlD
Afatinib—EGFR—testis—sarcoma	0.000619	0.0109	CbGeAlD
Afatinib—Vandetanib—EGFR—sarcoma	0.000601	0.0932	CrCbGaD
Afatinib—PHKG2—lymph node—sarcoma	0.000588	0.0104	CbGeAlD
Afatinib—ABL1—seminal vesicle—sarcoma	0.000587	0.0104	CbGeAlD
Afatinib—EGFR—liver—sarcoma	0.000585	0.0103	CbGeAlD
Afatinib—Gefitinib—EGFR—sarcoma	0.000571	0.0885	CrCbGaD
Afatinib—ABL1—hematopoietic system—sarcoma	0.000558	0.00985	CbGeAlD
Afatinib—IRAK1—testis—sarcoma	0.000546	0.00963	CbGeAlD
Afatinib—ABL1—connective tissue—sarcoma	0.000537	0.00948	CbGeAlD
Afatinib—LCK—testis—sarcoma	0.000532	0.00939	CbGeAlD
Afatinib—ERBB2—lymph node—sarcoma	0.000529	0.00933	CbGeAlD
Afatinib—ERBB2—Podofilox—Etoposide—sarcoma	0.000521	0.122	CbGdCrCtD
Afatinib—IRAK1—liver—sarcoma	0.000516	0.00911	CbGeAlD
Afatinib—DYRK1A—lymph node—sarcoma	0.000509	0.00899	CbGeAlD
Afatinib—LCK—liver—sarcoma	0.000503	0.00888	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—sarcoma	0.000492	0.00867	CbGeAlD
Afatinib—ABL1—skin of body—sarcoma	0.000485	0.00856	CbGeAlD
Afatinib—EGFR—lymph node—sarcoma	0.000449	0.00791	CbGeAlD
Afatinib—ABL1—cardiac atrium—sarcoma	0.000424	0.00748	CbGeAlD
Afatinib—ABL1—uterus—sarcoma	0.000422	0.00744	CbGeAlD
Afatinib—ABCG2—myometrium—sarcoma	0.00041	0.00723	CbGeAlD
Afatinib—Pneumonia—Thiotepa—sarcoma	0.000403	0.00549	CcSEcCtD
Afatinib—Infestation NOS—Thiotepa—sarcoma	0.0004	0.00546	CcSEcCtD
Afatinib—Infestation—Thiotepa—sarcoma	0.0004	0.00546	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—sarcoma	0.000399	0.00545	CcSEcCtD
Afatinib—IRAK1—lymph node—sarcoma	0.000396	0.00698	CbGeAlD
Afatinib—Alanine aminotransferase increased—Mitoxantrone—sarcoma	0.000396	0.0054	CcSEcCtD
Afatinib—Renal failure—Thiotepa—sarcoma	0.000393	0.00537	CcSEcCtD
Afatinib—ABL1—lymphoid tissue—sarcoma	0.000393	0.00693	CbGeAlD
Afatinib—Stomatitis—Thiotepa—sarcoma	0.00039	0.00532	CcSEcCtD
Afatinib—Conjunctivitis—Thiotepa—sarcoma	0.000389	0.00531	CcSEcCtD
Afatinib—Stomatitis—Dactinomycin—sarcoma	0.000387	0.00528	CcSEcCtD
Afatinib—LCK—lymph node—sarcoma	0.000386	0.00681	CbGeAlD
Afatinib—Hepatobiliary disease—Thiotepa—sarcoma	0.000378	0.00517	CcSEcCtD
Afatinib—Epistaxis—Thiotepa—sarcoma	0.000377	0.00515	CcSEcCtD
Afatinib—ABCG2—seminal vesicle—sarcoma	0.00037	0.00653	CbGeAlD
Afatinib—ABL1—tendon—sarcoma	0.000369	0.00652	CbGeAlD
Afatinib—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.00036	0.00492	CcSEcCtD
Afatinib—Weight decreased—Vincristine—sarcoma	0.00036	0.00491	CcSEcCtD
Afatinib—ABL1—bone marrow—sarcoma	0.000358	0.00631	CbGeAlD
Afatinib—Pneumonia—Vincristine—sarcoma	0.000357	0.00487	CcSEcCtD
Afatinib—Urinary tract disorder—Thiotepa—sarcoma	0.000355	0.00484	CcSEcCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—sarcoma	0.000353	0.083	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—sarcoma	0.000353	0.083	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—sarcoma	0.000353	0.083	CbGdCrCtD
Afatinib—Connective tissue disorder—Thiotepa—sarcoma	0.000353	0.00482	CcSEcCtD
Afatinib—Urethral disorder—Thiotepa—sarcoma	0.000352	0.00481	CcSEcCtD
Afatinib—Weight decreased—Mitoxantrone—sarcoma	0.000351	0.00479	CcSEcCtD
Afatinib—Pneumonia—Mitoxantrone—sarcoma	0.000348	0.00474	CcSEcCtD
Afatinib—Stomatitis—Vincristine—sarcoma	0.000346	0.00472	CcSEcCtD
Afatinib—Renal failure—Mitoxantrone—sarcoma	0.00034	0.00464	CcSEcCtD
Afatinib—Stomatitis—Mitoxantrone—sarcoma	0.000337	0.0046	CcSEcCtD
Afatinib—Urinary tract infection—Mitoxantrone—sarcoma	0.000336	0.00459	CcSEcCtD
Afatinib—Conjunctivitis—Mitoxantrone—sarcoma	0.000336	0.00459	CcSEcCtD
Afatinib—Eye disorder—Thiotepa—sarcoma	0.000336	0.00458	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Etoposide—sarcoma	0.000329	0.00449	CcSEcCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—sarcoma	0.000327	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—sarcoma	0.000327	0.0768	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—sarcoma	0.000327	0.0768	CbGdCrCtD
Afatinib—Mediastinal disorder—Thiotepa—sarcoma	0.000324	0.00442	CcSEcCtD
Afatinib—Alopecia—Thiotepa—sarcoma	0.000317	0.00433	CcSEcCtD
Afatinib—Alopecia—Dactinomycin—sarcoma	0.000315	0.0043	CcSEcCtD
Afatinib—Mental disorder—Thiotepa—sarcoma	0.000315	0.0043	CcSEcCtD
Afatinib—Urinary tract disorder—Vincristine—sarcoma	0.000315	0.00429	CcSEcCtD
Afatinib—Connective tissue disorder—Vincristine—sarcoma	0.000313	0.00427	CcSEcCtD
Afatinib—Malnutrition—Thiotepa—sarcoma	0.000313	0.00427	CcSEcCtD
Afatinib—Urethral disorder—Vincristine—sarcoma	0.000312	0.00426	CcSEcCtD
Afatinib—ABL1—testis—sarcoma	0.000306	0.0054	CbGeAlD
Afatinib—Back pain—Thiotepa—sarcoma	0.000303	0.00413	CcSEcCtD
Afatinib—Pneumonia—Etoposide—sarcoma	0.000289	0.00395	CcSEcCtD
Afatinib—ABL1—liver—sarcoma	0.000289	0.0051	CbGeAlD
Afatinib—Infestation NOS—Etoposide—sarcoma	0.000287	0.00392	CcSEcCtD
Afatinib—Infestation—Etoposide—sarcoma	0.000287	0.00392	CcSEcCtD
Afatinib—Mediastinal disorder—Vincristine—sarcoma	0.000287	0.00392	CcSEcCtD
Afatinib—Renal failure—Etoposide—sarcoma	0.000283	0.00386	CcSEcCtD
Afatinib—Alopecia—Vincristine—sarcoma	0.000282	0.00384	CcSEcCtD
Afatinib—Cystitis noninfective—Epirubicin—sarcoma	0.000281	0.00384	CcSEcCtD
Afatinib—Stomatitis—Etoposide—sarcoma	0.00028	0.00382	CcSEcCtD
Afatinib—Mental disorder—Vincristine—sarcoma	0.000279	0.00381	CcSEcCtD
Afatinib—Cystitis—Epirubicin—sarcoma	0.000278	0.0038	CcSEcCtD
Afatinib—Alopecia—Mitoxantrone—sarcoma	0.000274	0.00374	CcSEcCtD
Afatinib—Cough—Thiotepa—sarcoma	0.000273	0.00372	CcSEcCtD
Afatinib—Hepatobiliary disease—Etoposide—sarcoma	0.000272	0.00371	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—sarcoma	0.000272	0.0638	CbGdCrCtD
Afatinib—Back pain—Vincristine—sarcoma	0.000268	0.00366	CcSEcCtD
Afatinib—Dry eye—Epirubicin—sarcoma	0.000266	0.00363	CcSEcCtD
Afatinib—ABCG2—uterus—sarcoma	0.000266	0.00469	CbGeAlD
Afatinib—Dysgeusia—Mitoxantrone—sarcoma	0.000264	0.00361	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000264	0.00361	CcSEcCtD
Afatinib—Back pain—Mitoxantrone—sarcoma	0.000261	0.00357	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—sarcoma	0.00026	0.00355	CcSEcCtD
Afatinib—Mouth ulceration—Epirubicin—sarcoma	0.00026	0.00355	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—sarcoma	0.00026	0.00355	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—sarcoma	0.000257	0.00351	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—sarcoma	0.000255	0.00348	CcSEcCtD
Afatinib—Infection—Thiotepa—sarcoma	0.000254	0.00346	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—sarcoma	0.000253	0.00345	CcSEcCtD
Afatinib—Infection—Dactinomycin—sarcoma	0.000252	0.00344	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—sarcoma	0.000252	0.0591	CbGdCrCtD
Afatinib—Nervous system disorder—Thiotepa—sarcoma	0.00025	0.00342	CcSEcCtD
Afatinib—Sepsis—Epirubicin—sarcoma	0.00025	0.00341	CcSEcCtD
Afatinib—Skin disorder—Thiotepa—sarcoma	0.000248	0.00338	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—sarcoma	0.000246	0.00336	CcSEcCtD
Afatinib—Eye disorder—Etoposide—sarcoma	0.000241	0.00329	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—sarcoma	0.000241	0.00329	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—sarcoma	0.000241	0.00329	CcSEcCtD
Afatinib—Cough—Mitoxantrone—sarcoma	0.000236	0.00322	CcSEcCtD
Afatinib—Mediastinal disorder—Etoposide—sarcoma	0.000233	0.00317	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—sarcoma	0.000231	0.00316	CcSEcCtD
Afatinib—Alopecia—Etoposide—sarcoma	0.000228	0.00311	CcSEcCtD
Afatinib—ABCG2—bone marrow—sarcoma	0.000226	0.00398	CbGeAlD
Afatinib—Infection—Vincristine—sarcoma	0.000225	0.00307	CcSEcCtD
Afatinib—Dyspepsia—Thiotepa—sarcoma	0.000225	0.00307	CcSEcCtD
Afatinib—Nervous system disorder—Vincristine—sarcoma	0.000222	0.00303	CcSEcCtD
Afatinib—Decreased appetite—Thiotepa—sarcoma	0.000222	0.00303	CcSEcCtD
Afatinib—ABL1—lymph node—sarcoma	0.000222	0.00391	CbGeAlD
Afatinib—Gastrointestinal disorder—Thiotepa—sarcoma	0.00022	0.00301	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—sarcoma	0.00022	0.00301	CcSEcCtD
Afatinib—Fatigue—Thiotepa—sarcoma	0.00022	0.003	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—sarcoma	0.00022	0.003	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—sarcoma	0.00022	0.003	CcSEcCtD
Afatinib—Infection—Mitoxantrone—sarcoma	0.000219	0.00299	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—sarcoma	0.000218	0.00298	CcSEcCtD
Afatinib—Constipation—Thiotepa—sarcoma	0.000218	0.00298	CcSEcCtD
Afatinib—Back pain—Etoposide—sarcoma	0.000217	0.00297	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—sarcoma	0.000216	0.00295	CcSEcCtD
Afatinib—Skin disorder—Mitoxantrone—sarcoma	0.000214	0.00292	CcSEcCtD
Afatinib—Insomnia—Vincristine—sarcoma	0.000205	0.00279	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—sarcoma	0.000203	0.00277	CcSEcCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000203	0.0477	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000203	0.0477	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000203	0.0477	CbGdCrCtD
Afatinib—ABCB1—myometrium—sarcoma	0.000202	0.00357	CbGeAlD
Afatinib—Body temperature increased—Thiotepa—sarcoma	0.000202	0.00275	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—sarcoma	0.0002	0.00273	CcSEcCtD
Afatinib—Decreased appetite—Vincristine—sarcoma	0.000197	0.00269	CcSEcCtD
Afatinib—Dyspnoea—Mitoxantrone—sarcoma	0.000197	0.00268	CcSEcCtD
Afatinib—Cough—Etoposide—sarcoma	0.000196	0.00268	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vincristine—sarcoma	0.000195	0.00267	CcSEcCtD
Afatinib—Fatigue—Vincristine—sarcoma	0.000195	0.00266	CcSEcCtD
Afatinib—Dehydration—Epirubicin—sarcoma	0.000194	0.00265	CcSEcCtD
Afatinib—ABCB1—embryo—sarcoma	0.000194	0.00343	CbGeAlD
Afatinib—Dyspepsia—Mitoxantrone—sarcoma	0.000194	0.00265	CcSEcCtD
Afatinib—Constipation—Vincristine—sarcoma	0.000194	0.00264	CcSEcCtD
Afatinib—ABCG2—testis—sarcoma	0.000193	0.0034	CbGeAlD
Afatinib—Dry skin—Epirubicin—sarcoma	0.000192	0.00262	CcSEcCtD
Afatinib—Decreased appetite—Mitoxantrone—sarcoma	0.000192	0.00262	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—sarcoma	0.00019	0.0026	CcSEcCtD
Afatinib—Fatigue—Mitoxantrone—sarcoma	0.00019	0.00259	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00019	0.00259	CcSEcCtD
Afatinib—Constipation—Mitoxantrone—sarcoma	0.000188	0.00257	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000188	0.00257	CcSEcCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000188	0.0441	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000188	0.0441	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000188	0.0441	CbGdCrCtD
Afatinib—Nasopharyngitis—Epirubicin—sarcoma	0.000187	0.00255	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000184	0.00252	CcSEcCtD
Afatinib—Asthenia—Thiotepa—sarcoma	0.000183	0.0025	CcSEcCtD
Afatinib—ABCB1—seminal vesicle—sarcoma	0.000183	0.00322	CbGeAlD
Afatinib—ABCG2—liver—sarcoma	0.000182	0.00322	CbGeAlD
Afatinib—Infection—Etoposide—sarcoma	0.000182	0.00249	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—sarcoma	0.000182	0.00248	CcSEcCtD
Afatinib—Pruritus—Thiotepa—sarcoma	0.000181	0.00246	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—sarcoma	0.00018	0.00246	CcSEcCtD
Afatinib—Body temperature increased—Vincristine—sarcoma	0.000179	0.00244	CcSEcCtD
Afatinib—Skin disorder—Etoposide—sarcoma	0.000178	0.00243	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—sarcoma	0.000177	0.00242	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—sarcoma	0.000176	0.0024	CcSEcCtD
Afatinib—Diarrhoea—Thiotepa—sarcoma	0.000175	0.00238	CcSEcCtD
Afatinib—Body temperature increased—Mitoxantrone—sarcoma	0.000174	0.00238	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000174	0.00238	CcSEcCtD
Afatinib—ABCB1—hematopoietic system—sarcoma	0.000174	0.00306	CbGeAlD
Afatinib—Diarrhoea—Dactinomycin—sarcoma	0.000173	0.00237	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—sarcoma	0.000173	0.00236	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000171	0.00233	CcSEcCtD
Afatinib—Dizziness—Thiotepa—sarcoma	0.000169	0.0023	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—sarcoma	0.000168	0.00229	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—sarcoma	0.000164	0.00223	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—sarcoma	0.000163	0.00223	CcSEcCtD
Afatinib—Asthenia—Vincristine—sarcoma	0.000162	0.00222	CcSEcCtD
Afatinib—Vomiting—Thiotepa—sarcoma	0.000162	0.00222	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—sarcoma	0.000162	0.00221	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—sarcoma	0.000161	0.0022	CcSEcCtD
Afatinib—Infestation—Epirubicin—sarcoma	0.000161	0.0022	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—sarcoma	0.000161	0.0022	CcSEcCtD
Afatinib—Rash—Thiotepa—sarcoma	0.000161	0.0022	CcSEcCtD
Afatinib—Dermatitis—Thiotepa—sarcoma	0.000161	0.00219	CcSEcCtD
Afatinib—Headache—Thiotepa—sarcoma	0.00016	0.00218	CcSEcCtD
Afatinib—Rash—Dactinomycin—sarcoma	0.00016	0.00218	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—sarcoma	0.000159	0.00218	CcSEcCtD
Afatinib—Renal failure—Epirubicin—sarcoma	0.000158	0.00216	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—sarcoma	0.000158	0.00216	CcSEcCtD
Afatinib—Asthenia—Mitoxantrone—sarcoma	0.000158	0.00216	CcSEcCtD
Afatinib—Fatigue—Etoposide—sarcoma	0.000158	0.00216	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—sarcoma	0.000157	0.00214	CcSEcCtD
Afatinib—Constipation—Etoposide—sarcoma	0.000157	0.00214	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—sarcoma	0.000157	0.00214	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—sarcoma	0.000157	0.00214	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000155	0.00212	CcSEcCtD
Afatinib—Diarrhoea—Vincristine—sarcoma	0.000155	0.00211	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—sarcoma	0.000152	0.00208	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—sarcoma	0.000152	0.00207	CcSEcCtD
Afatinib—Nausea—Thiotepa—sarcoma	0.000152	0.00207	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—sarcoma	0.000151	0.00206	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—sarcoma	0.000151	0.00206	CcSEcCtD
Afatinib—Nausea—Dactinomycin—sarcoma	0.00015	0.00205	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—sarcoma	0.00015	0.00205	CcSEcCtD
Afatinib—Dizziness—Vincristine—sarcoma	0.00015	0.00204	CcSEcCtD
Afatinib—Infestation—Doxorubicin—sarcoma	0.000149	0.00204	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—sarcoma	0.000149	0.00204	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—sarcoma	0.000147	0.002	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—sarcoma	0.000145	0.00198	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—sarcoma	0.000145	0.00198	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—sarcoma	0.000145	0.00198	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—sarcoma	0.000145	0.00198	CcSEcCtD
Afatinib—Vomiting—Vincristine—sarcoma	0.000144	0.00196	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—sarcoma	0.000143	0.00195	CcSEcCtD
Afatinib—Rash—Vincristine—sarcoma	0.000143	0.00195	CcSEcCtD
Afatinib—Dermatitis—Vincristine—sarcoma	0.000143	0.00195	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—sarcoma	0.000142	0.00194	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—sarcoma	0.000142	0.00194	CcSEcCtD
Afatinib—Headache—Vincristine—sarcoma	0.000142	0.00194	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—sarcoma	0.000141	0.00192	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—sarcoma	0.000141	0.00192	CcSEcCtD
Afatinib—Vomiting—Mitoxantrone—sarcoma	0.00014	0.00191	CcSEcCtD
Afatinib—ABCG2—lymph node—sarcoma	0.00014	0.00247	CbGeAlD
Afatinib—Rash—Mitoxantrone—sarcoma	0.000139	0.0019	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—sarcoma	0.000139	0.0019	CcSEcCtD
Afatinib—Headache—Mitoxantrone—sarcoma	0.000138	0.00188	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—sarcoma	0.000135	0.00185	CcSEcCtD
Afatinib—Nausea—Vincristine—sarcoma	0.000134	0.00183	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—sarcoma	0.000132	0.0018	CcSEcCtD
Afatinib—Asthenia—Etoposide—sarcoma	0.000132	0.0018	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—sarcoma	0.000132	0.0018	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—sarcoma	0.000131	0.00179	CcSEcCtD
Afatinib—ABCB1—uterus—sarcoma	0.000131	0.00231	CbGeAlD
Afatinib—Nausea—Mitoxantrone—sarcoma	0.000131	0.00179	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—sarcoma	0.00013	0.00178	CcSEcCtD
Afatinib—Pruritus—Etoposide—sarcoma	0.00013	0.00177	CcSEcCtD
Afatinib—Alopecia—Epirubicin—sarcoma	0.000128	0.00174	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—sarcoma	0.000127	0.00173	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—sarcoma	0.000126	0.00172	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—sarcoma	0.000125	0.00171	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—sarcoma	0.000125	0.00171	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—sarcoma	0.000123	0.00168	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—sarcoma	0.000122	0.00216	CbGeAlD
Afatinib—Back pain—Epirubicin—sarcoma	0.000122	0.00166	CcSEcCtD
Afatinib—Dizziness—Etoposide—sarcoma	0.000121	0.00165	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—sarcoma	0.000121	0.00165	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—sarcoma	0.000121	0.00165	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—sarcoma	0.000118	0.00161	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—sarcoma	0.000117	0.0016	CcSEcCtD
Afatinib—Vomiting—Etoposide—sarcoma	0.000117	0.00159	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—sarcoma	0.000117	0.00159	CcSEcCtD
Afatinib—Rash—Etoposide—sarcoma	0.000116	0.00158	CcSEcCtD
Afatinib—Dermatitis—Etoposide—sarcoma	0.000115	0.00158	CcSEcCtD
Afatinib—Headache—Etoposide—sarcoma	0.000115	0.00157	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—sarcoma	0.000114	0.00156	CcSEcCtD
Afatinib—Back pain—Doxorubicin—sarcoma	0.000113	0.00154	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—sarcoma	0.000112	0.00153	CcSEcCtD
Afatinib—ABCB1—bone marrow—sarcoma	0.000111	0.00196	CbGeAlD
Afatinib—Cough—Epirubicin—sarcoma	0.00011	0.0015	CcSEcCtD
Afatinib—Nausea—Etoposide—sarcoma	0.000109	0.00149	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000106	0.00145	CcSEcCtD
Afatinib—Infection—Epirubicin—sarcoma	0.000102	0.00139	CcSEcCtD
Afatinib—Cough—Doxorubicin—sarcoma	0.000102	0.00139	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—sarcoma	0.000101	0.00138	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—sarcoma	9.98e-05	0.00136	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	9.85e-05	0.00134	CcSEcCtD
Afatinib—ABCB1—testis—sarcoma	9.51e-05	0.00168	CbGeAlD
Afatinib—Infection—Doxorubicin—sarcoma	9.45e-05	0.00129	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—sarcoma	9.33e-05	0.00127	CcSEcCtD
Afatinib—Insomnia—Epirubicin—sarcoma	9.3e-05	0.00127	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—sarcoma	9.24e-05	0.00126	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—sarcoma	9.16e-05	0.00125	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—sarcoma	9.05e-05	0.00123	CcSEcCtD
Afatinib—ABCB1—liver—sarcoma	8.99e-05	0.00159	CbGeAlD
Afatinib—Decreased appetite—Epirubicin—sarcoma	8.93e-05	0.00122	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—sarcoma	8.87e-05	0.00121	CcSEcCtD
Afatinib—Fatigue—Epirubicin—sarcoma	8.86e-05	0.00121	CcSEcCtD
Afatinib—Constipation—Epirubicin—sarcoma	8.79e-05	0.0012	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—sarcoma	8.6e-05	0.00117	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—sarcoma	8.48e-05	0.00116	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—sarcoma	8.37e-05	0.00114	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—sarcoma	8.27e-05	0.00113	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—sarcoma	8.21e-05	0.00112	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—sarcoma	8.2e-05	0.00112	CcSEcCtD
Afatinib—Constipation—Doxorubicin—sarcoma	8.13e-05	0.00111	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—sarcoma	8.12e-05	0.00111	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—sarcoma	7.52e-05	0.00103	CcSEcCtD
Afatinib—Asthenia—Epirubicin—sarcoma	7.37e-05	0.00101	CcSEcCtD
Afatinib—Pruritus—Epirubicin—sarcoma	7.27e-05	0.000992	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—sarcoma	7.03e-05	0.00096	CcSEcCtD
Afatinib—ABCB1—lymph node—sarcoma	6.89e-05	0.00122	CbGeAlD
Afatinib—Asthenia—Doxorubicin—sarcoma	6.82e-05	0.000931	CcSEcCtD
Afatinib—Dizziness—Epirubicin—sarcoma	6.8e-05	0.000928	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—sarcoma	6.73e-05	0.000918	CcSEcCtD
Afatinib—Vomiting—Epirubicin—sarcoma	6.53e-05	0.000892	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—sarcoma	6.51e-05	0.000888	CcSEcCtD
Afatinib—Rash—Epirubicin—sarcoma	6.48e-05	0.000884	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—sarcoma	6.47e-05	0.000884	CcSEcCtD
Afatinib—Headache—Epirubicin—sarcoma	6.44e-05	0.000879	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—sarcoma	6.29e-05	0.000858	CcSEcCtD
Afatinib—Nausea—Epirubicin—sarcoma	6.1e-05	0.000833	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—sarcoma	6.05e-05	0.000825	CcSEcCtD
Afatinib—Rash—Doxorubicin—sarcoma	6e-05	0.000818	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—sarcoma	5.99e-05	0.000818	CcSEcCtD
Afatinib—Headache—Doxorubicin—sarcoma	5.96e-05	0.000813	CcSEcCtD
Afatinib—Nausea—Doxorubicin—sarcoma	5.65e-05	0.000771	CcSEcCtD
Afatinib—ERBB2—Immune System—SRC—sarcoma	1.11e-05	7.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FOXO1—sarcoma	1.1e-05	7.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PDGFRB—sarcoma	1.1e-05	7.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FOXO1—sarcoma	1.1e-05	7.02e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PDGFRB—sarcoma	1.1e-05	7.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.09e-05	6.97e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CREB1—sarcoma	1.09e-05	6.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—sarcoma	1.09e-05	6.96e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—MDM2—sarcoma	1.09e-05	6.94e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—SRC—sarcoma	1.09e-05	6.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PDGFRA—sarcoma	1.09e-05	6.92e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PDGFRA—sarcoma	1.08e-05	6.9e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—SRC—sarcoma	1.07e-05	6.85e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EGFR—sarcoma	1.07e-05	6.8e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NRAS—sarcoma	1.06e-05	6.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FLT1—sarcoma	1.06e-05	6.75e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—FOXO1—sarcoma	1.05e-05	6.73e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PDGFRB—sarcoma	1.05e-05	6.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NRAS—sarcoma	1.05e-05	6.68e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—SRC—sarcoma	1.05e-05	6.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PLCG1—sarcoma	1.04e-05	6.64e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—SRC—sarcoma	1.04e-05	6.63e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PDGFRA—sarcoma	1.04e-05	6.61e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NRAS—sarcoma	1.03e-05	6.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MDM2—sarcoma	1.02e-05	6.54e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—sarcoma	1.02e-05	6.53e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—JUN—sarcoma	1.02e-05	6.52e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—SRC—sarcoma	1.02e-05	6.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FLT1—sarcoma	1.02e-05	6.51e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KIT—sarcoma	1.02e-05	6.5e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FOXO1—sarcoma	1.02e-05	6.48e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CTNNB1—sarcoma	1.01e-05	6.47e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PDGFRB—sarcoma	1.01e-05	6.47e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—VEGFA—sarcoma	1.01e-05	6.45e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—NRAS—sarcoma	1.01e-05	6.43e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—KRAS—sarcoma	1.01e-05	6.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—SRC—sarcoma	1.01e-05	6.41e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1e-05	6.41e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PLCG1—sarcoma	1e-05	6.4e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCR4—sarcoma	1e-05	6.38e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NRAS—sarcoma	9.99e-06	6.37e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PDGFRA—sarcoma	9.99e-06	6.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ATF1—sarcoma	9.89e-06	6.31e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—KRAS—sarcoma	9.87e-06	6.3e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—JUN—sarcoma	9.86e-06	6.29e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	9.83e-06	6.27e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—SRC—sarcoma	9.82e-06	6.26e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—sarcoma	9.82e-06	6.26e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CTNNB1—sarcoma	9.78e-06	6.24e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CREB1—sarcoma	9.69e-06	6.18e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EGFR—sarcoma	9.69e-06	6.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—sarcoma	9.67e-06	6.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—sarcoma	9.66e-06	6.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCR4—sarcoma	9.63e-06	6.15e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—VEGFA—sarcoma	9.56e-06	6.1e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—sarcoma	9.54e-06	6.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ATF1—sarcoma	9.53e-06	6.08e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—sarcoma	9.45e-06	6.03e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—sarcoma	9.41e-06	6e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	9.28e-06	5.92e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—sarcoma	9.18e-06	5.85e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—SRC—sarcoma	9.17e-06	5.85e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MDM2—sarcoma	9.17e-06	5.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—sarcoma	9.16e-06	5.84e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—sarcoma	9.15e-06	5.84e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—sarcoma	9.14e-06	5.83e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KDR—sarcoma	9.13e-06	5.83e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CREB1—sarcoma	9.07e-06	5.78e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MDM2—sarcoma	9.03e-06	5.76e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—sarcoma	9.01e-06	5.75e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—sarcoma	9.01e-06	5.75e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—sarcoma	8.94e-06	5.7e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—JUN—sarcoma	8.91e-06	5.68e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—sarcoma	8.89e-06	5.67e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—SRC—sarcoma	8.84e-06	5.64e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CTNNB1—sarcoma	8.84e-06	5.64e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—sarcoma	8.83e-06	5.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—sarcoma	8.81e-06	5.62e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—SRC—sarcoma	8.81e-06	5.62e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—sarcoma	8.78e-06	5.6e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KIT—sarcoma	8.7e-06	5.55e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—sarcoma	8.67e-06	5.53e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—sarcoma	8.6e-06	5.49e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—sarcoma	8.56e-06	5.46e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—sarcoma	8.51e-06	5.42e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—SRC—sarcoma	8.49e-06	5.41e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—sarcoma	8.47e-06	5.41e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—sarcoma	8.45e-06	5.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KIT—sarcoma	8.41e-06	5.37e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—sarcoma	8.39e-06	5.35e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KIT—sarcoma	8.39e-06	5.35e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—sarcoma	8.32e-06	5.31e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CREB1—sarcoma	8.28e-06	5.28e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	8.25e-06	5.26e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—sarcoma	8.19e-06	5.22e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—sarcoma	8.17e-06	5.21e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—sarcoma	8.13e-06	5.19e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—sarcoma	8.07e-06	5.15e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KIT—sarcoma	8.03e-06	5.12e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MDM2—sarcoma	8.02e-06	5.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CREB1—sarcoma	8.01e-06	5.11e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—SRC—sarcoma	7.99e-06	5.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—sarcoma	7.98e-06	5.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CREB1—sarcoma	7.98e-06	5.09e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—JUN—sarcoma	7.97e-06	5.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CTNNB1—sarcoma	7.91e-06	5.04e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—sarcoma	7.86e-06	5.02e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—JUN—sarcoma	7.85e-06	5.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CTNNB1—sarcoma	7.79e-06	4.97e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—sarcoma	7.78e-06	4.96e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1R—sarcoma	7.76e-06	4.95e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—sarcoma	7.75e-06	4.94e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KIT—sarcoma	7.74e-06	4.94e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—sarcoma	7.69e-06	4.9e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—sarcoma	7.66e-06	4.89e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CREB1—sarcoma	7.65e-06	4.88e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—sarcoma	7.6e-06	4.84e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—sarcoma	7.56e-06	4.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1R—sarcoma	7.48e-06	4.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—sarcoma	7.44e-06	4.75e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—sarcoma	7.4e-06	4.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FOXO1—sarcoma	7.38e-06	4.71e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—sarcoma	7.37e-06	4.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFRB—sarcoma	7.37e-06	4.7e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CREB1—sarcoma	7.37e-06	4.7e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HBA1—sarcoma	7.36e-06	4.69e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—sarcoma	7.32e-06	4.67e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—sarcoma	7.31e-06	4.66e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—sarcoma	7.29e-06	4.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDGFRA—sarcoma	7.26e-06	4.63e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—sarcoma	7.23e-06	4.61e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—sarcoma	7.18e-06	4.58e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—sarcoma	7.17e-06	4.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SRC—sarcoma	7.15e-06	4.56e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO1—sarcoma	7.12e-06	4.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFRB—sarcoma	7.1e-06	4.53e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—sarcoma	7.07e-06	4.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SRC—sarcoma	7.04e-06	4.49e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—sarcoma	7.03e-06	4.48e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—sarcoma	7e-06	4.47e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDGFRA—sarcoma	6.99e-06	4.46e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—JUN—sarcoma	6.97e-06	4.45e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—sarcoma	6.96e-06	4.44e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CTNNB1—sarcoma	6.92e-06	4.41e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—sarcoma	6.91e-06	4.41e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—sarcoma	6.87e-06	4.38e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—sarcoma	6.86e-06	4.37e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MDM2—sarcoma	6.85e-06	4.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—sarcoma	6.77e-06	4.32e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—sarcoma	6.7e-06	4.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MDM2—sarcoma	6.63e-06	4.23e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—sarcoma	6.62e-06	4.22e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MDM2—sarcoma	6.6e-06	4.21e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—sarcoma	6.46e-06	4.12e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—sarcoma	6.4e-06	4.08e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MDM2—sarcoma	6.33e-06	4.04e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—sarcoma	6.31e-06	4.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLCG1—sarcoma	6.28e-06	4.01e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—sarcoma	6.26e-06	3.99e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—sarcoma	6.25e-06	3.99e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—sarcoma	6.22e-06	3.97e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—sarcoma	6.2e-06	3.95e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—sarcoma	6.17e-06	3.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—sarcoma	6.12e-06	3.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KDR—sarcoma	6.11e-06	3.9e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MDM2—sarcoma	6.1e-06	3.89e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—sarcoma	6.02e-06	3.84e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—sarcoma	5.97e-06	3.81e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—sarcoma	5.96e-06	3.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—sarcoma	5.92e-06	3.78e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—sarcoma	5.92e-06	3.77e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—sarcoma	5.91e-06	3.77e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—sarcoma	5.9e-06	3.76e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—sarcoma	5.89e-06	3.75e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—sarcoma	5.83e-06	3.72e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—sarcoma	5.77e-06	3.68e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—sarcoma	5.76e-06	3.67e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—sarcoma	5.74e-06	3.66e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—sarcoma	5.72e-06	3.65e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—sarcoma	5.7e-06	3.63e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—sarcoma	5.63e-06	3.59e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—sarcoma	5.63e-06	3.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—sarcoma	5.62e-06	3.59e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—sarcoma	5.48e-06	3.5e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—sarcoma	5.46e-06	3.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—sarcoma	5.42e-06	3.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREB1—sarcoma	5.36e-06	3.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—sarcoma	5.34e-06	3.41e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—sarcoma	5.26e-06	3.35e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—sarcoma	5.26e-06	3.35e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—sarcoma	5.18e-06	3.3e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—sarcoma	5.18e-06	3.3e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—sarcoma	5.17e-06	3.3e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREB1—sarcoma	5.16e-06	3.29e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—sarcoma	5.15e-06	3.28e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—sarcoma	5.14e-06	3.28e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	5.03e-06	3.21e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—sarcoma	5.03e-06	3.21e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—sarcoma	4.97e-06	3.17e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—sarcoma	4.95e-06	3.16e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—sarcoma	4.95e-06	3.16e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—sarcoma	4.93e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—sarcoma	4.84e-06	3.09e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—sarcoma	4.75e-06	3.03e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—sarcoma	4.75e-06	3.03e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—sarcoma	4.63e-06	2.95e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—sarcoma	4.57e-06	2.92e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—sarcoma	4.53e-06	2.89e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—sarcoma	4.51e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—sarcoma	4.43e-06	2.83e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—sarcoma	4.42e-06	2.82e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—sarcoma	4.42e-06	2.82e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—sarcoma	4.4e-06	2.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—sarcoma	4.28e-06	2.73e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—sarcoma	4.27e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—sarcoma	4.26e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—sarcoma	4.26e-06	2.72e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—sarcoma	4.17e-06	2.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—sarcoma	4.12e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—sarcoma	4.08e-06	2.61e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—sarcoma	3.96e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—sarcoma	3.94e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—sarcoma	3.86e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—sarcoma	3.85e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—sarcoma	3.82e-06	2.44e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—sarcoma	3.82e-06	2.43e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—sarcoma	3.8e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—sarcoma	3.76e-06	2.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—sarcoma	3.72e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—sarcoma	3.71e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—sarcoma	3.68e-06	2.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—sarcoma	3.64e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—sarcoma	3.62e-06	2.31e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—sarcoma	3.47e-06	2.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—sarcoma	3.45e-06	2.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—sarcoma	3.36e-06	2.15e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—sarcoma	3.35e-06	2.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—sarcoma	3.33e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—sarcoma	3.32e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—sarcoma	3.24e-06	2.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—sarcoma	3.2e-06	2.04e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—sarcoma	3.1e-06	1.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—sarcoma	2.98e-06	1.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—sarcoma	2.92e-06	1.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—sarcoma	2.86e-06	1.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—sarcoma	2.76e-06	1.76e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—sarcoma	2.54e-06	1.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—sarcoma	2.45e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—sarcoma	2.43e-06	1.55e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—sarcoma	2.34e-06	1.49e-05	CbGpPWpGaD
